Physician profile
Diana Pan
NPI 1447770680
$4,244.76
in general payments reported to CMS, 2019-2025
10 companies · $690 in 2025
The $690 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,017 · 2021: $263 · 2022: $1,112 · 2023: $320 · 2024: $842 · 2025: $690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,852.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,102.69 | 2019-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $1,059.89 | 2022-2025 | Xiidra, Miebo, Infuse |
| Alcon Vision LLC | $726.27 | 2023-2025 | Precision 1, Dailies Total1, Total30 |
| Glaukos Corporation | $274.88 | 2024 | Ce-Marked Kxla System |
| Oyster Point Pharma, INC. | $273.89 | 2022 | |
| Sight Sciences, INC. | $222.19 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $221.11 | 2019-2021 | |
| Dompe US, INC. | $125.00 | 2025 | Oxervate |
| Allergan, INC. | $120.53 | 2022 | |
| Sun Pharmaceutical Industries INC. | $118.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Pan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.